转化成简体中文并保持原句结构：比较转移性炎性与非炎性乳腺癌患者肿瘤样本中存在的基因组改变，揭示了AURKA作为一个潜在的治疗靶点。
Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target.
发表日期：2023 Jan 25
作者：
François Richard, Maxim De Schepper, Marion Maetens, Sophia Leduc, Edoardo Isnaldi, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Peter Vermeulen, Steven Van Laere, François Bertucci, Naoto Ueno, Luc Dirix, Giuseppe Floris, Elia Biganzoli, Christine Desmedt
来源：
BREAST
摘要：
炎症性乳腺癌（IBC）是一种罕见但具有侵袭性的乳腺癌亚型，主要通过初诊肿瘤样本进行表征。在这里，我们使用公共数据集，对IBCM患者的转移性样本与转移性非IBC患者的原发性样本进行基因组变化比较。我们观察到IBC中AURKA扩增的频率更高。我们进一步显示AURKA扩增与AURKA mRNA表达增加相关，而我们证明IBC中AURKA mRNA表达更高。最后，AURKA的较高蛋白表达与IBC患者预后更差相关。考虑到AURKA抑制剂的存在，这些发现值得进一步研究。Copyright © 2023. Elsevier Ltd. 发布。
Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors.Copyright © 2023. Published by Elsevier Ltd.